Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Telix Pharmaceuticals
Biotech
Telix offers $33M to acquire Qsam and phase 1 bone cancer drug
Telix has offered to pay $33.1 million for Qsam Biosciences so the Australian biotech can get its hands on a phase 1 radiopharmaceutical.
James Waldron
Nov 14, 2023 8:20am
Agios replaces CEO after recent FDA nod—Chutes & Ladders
Jul 15, 2022 9:30am
Abzena licenses PSMA antibodies to Telix
Jul 18, 2017 8:46am